News ArticleSai Life Sciences Reports 23% Revenue Growth in Q2 FY27 with ₹621 Crore Capex Investment
Company maintains healthy 28% EBITDA margin and sees broad-based growth across CRO and CDMO segments in first half of FY27
Sai Life Sciences Limited announced a 23% year-on-year revenue increase to ₹659 crore in Q2 FY27, maintaining a 28% EBITDA margin and investing ₹621 crore in capacity expansion during H1 FY27. The company's strong financial performance reflects growing global pharmaceutical partnerships and strategic customer relationships.
Sai Life Sciences Limited
General / Other
Sai Life Sciences Limited posted a 23% year-on-year revenue increase to ₹659 crore for Q2 FY27, with sustained EBITDA margin of 28% and a capital expenditure of ₹621 crore invested during the first half of the fiscal year, as the company strengthens its global pharmaceutical partnerships and expands capacity.
The company reported revenue from operations of ₹659 crore for the quarter ended September 30, 2026, up from ₹537 crore in Q2 FY26, along with an EBITDA of ₹187 crore representing a 28% margin.
For the half year ended September 30, 2026, revenue reached ₹1,213 crore, a 17% increase compared to ₹1,034 crore in the previous year period, with EBITDA rising 19% to ₹335 crore and a PAT of ₹172 crore, up 19% year-on-year.
Both the Contract Research Organization (CRO) and Contract Development and Manufacturing Organization (CDMO) segments delivered healthy growth, supporting the overall strong financial performance.
The company invested ₹621 crore during H1 FY27 in capacity and capability expansion to sustain and support growing global customer engagements which are evolving into larger strategic projects spanning discovery, development, and manufacturing.
Highlights
- Q2 FY27 revenue from operations stood at ₹659 crore, a 23% increase year-on-year.
- EBITDA for Q2 FY27 was ₹187 crore, maintaining a 28% margin.
- PAT was ₹98 crore in Q2 FY27, a 17% increase year-on-year.
- Capex investment of ₹621 crore made in the first half of FY27.
- Revenue for H1 FY27 was ₹1,213 crore, up 17% year-over-year.
- EBITDA and PAT for H1 FY27 grew by 19% to ₹335 crore and ₹172 crore respectively.
Key Data Snapshot
What happened
- Sai Life Sciences recorded 23% year-on-year revenue growth in Q2 FY27 to ₹659 crore.
- EBITDA margins remained healthy at 28% for the quarter.
- The company achieved a PAT of ₹98 crore in Q2 FY27, improving 17% compared to the previous year.
- For H1 FY27, revenues rose 17% to ₹1,213 crore, with EBITDA and PAT up 19%.
- Capital expenditure totaled ₹621 crore in the first half of FY27 to expand capacity and capabilities.
Key details
- Growth was broad-based, with both Contract Research Organization (CRO) and Contract Development and Manufacturing Organization (CDMO) segments contributing.
- Customer relationships are evolving into larger strategic partnerships that span discovery, development, and commercial manufacturing.
- The company anticipates a stronger second half of FY27 driven by pipeline progression and capacity ramp-up.
Strategic context
- Sai Life Sciences is focused on delivering integrated outsourcing solutions to global pharmaceutical companies.
- The capacity and capability expansion program is on track, supporting the company’s long-term growth objectives.
- The company aims to maintain its position as one of India’s fastest growing CRDMOs by strengthening capabilities in emerging therapeutic modalities.
Highlights
- Q2 FY27 revenue from operations stood at ₹659 crore, a 23% increase year-on-year.
- EBITDA for Q2 FY27 was ₹187 crore, maintaining a 28% margin.
- PAT was ₹98 crore in Q2 FY27, a 17% increase year-on-year.
- Capex investment of ₹621 crore made in the first half of FY27.
- Revenue for H1 FY27 was ₹1,213 crore, up 17% year-over-year.
- EBITDA and PAT for H1 FY27 grew by 19% to ₹335 crore and ₹172 crore respectively.
Disclosures
- Regulation 30 of SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015
Source Information
More News on General / Other
View allLatest corporate announcements and market updates in General / Other.
Sansera Engineering Achieves Record INR 10,915 Million Quarterly Revenue and 59% Normalised PAT Growth in Q2 FY27
Sansera Engineering Limited reported its highest-ever quarterly revenue of INR 10,915 million for Q2 FY27, a 32% increase year-over-year, alongside a normalized profit after tax of INR 1,000 million, up 59% YoY excluding an exceptional litigation-related cost.
Read Full Story
Godfrey Phillips India Declares ₹10 Interim Dividend and Posts ₹16,298 Lakh Profit for Q2 FY2027
Godfrey Phillips India Limited declared an interim dividend of 500% or ₹10 per equity share for the financial year ending March 31, 2027, while reporting an unaudited standalone net profit of ₹16,298 lakh for the quarter ended September 30, 2026.
Read Full Story
IKS Health Doubles Revenue with 103.9% YoY Growth and Boosts EBITDA by 62.5% in Q2 FY27 Post TruBridge Deal
Inventurus Knowledge Solutions Limited (IKS Health) announced strong Q2 FY27 financial results with revenue surpassing INR 15,900 million, marking a 103.9% year-on-year increase supported by its TruBridge acquisition and sustained organic growth.
Read Full Story
